AbbVie Inc., announced the approval of upadacitinib (RINVOQ) for the treatment of active non-radiographic axial spondyloarthritis in patients with signs of inflammation who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Antisense Therapeutics Limited- announced a scientific exploration into a new muscle disease indication for ATL1102 – Limb Girdle Muscular Dystrophy R2.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?